CRH Medical (TSE:CRH) had its price objective raised by Royal Bank of Canada from C$4.50 to C$4.75 in a research note released on Wednesday morning. Royal Bank of Canada currently has an outperform rating on the stock.
Several other brokerages also recently issued reports on CRH. National Bank Financial raised their price target on CRH Medical from C$4.25 to C$4.50 and gave the stock an outperform rating in a report on Tuesday, March 6th. TD Securities raised their price target on CRH Medical from C$2.50 to C$3.50 and gave the stock a hold rating in a report on Wednesday, March 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. CRH Medical currently has a consensus rating of Buy and a consensus target price of C$4.50.
Get CRH Medical alerts:
Shares of TSE CRH opened at C$4.10 on Wednesday. CRH Medical has a 12-month low of C$1.86 and a 12-month high of C$8.76.
CRH Medical (TSE:CRH) last announced its quarterly earnings results on Monday, March 5th. The company reported C$0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.04 by C$0.01. The business had revenue of C$41.03 million for the quarter, compared to the consensus estimate of C$34.97 million. CRH Medical had a return on equity of 13.79% and a net margin of 14.77%.
About CRH Medical
CRH Medical Corporation provides products and services to physicians for the treatment of gastrointestinal diseases in the United States. It offers anesthesia services for patients undergoing endoscopic procedures; and CRH O'Regan System, a single use, disposable, and hemorrhoid banding technology for treating hemorrhoid grades I?IV.